Search - tctmd.com

Displaying 81 - 100 of 163

Sort: Relevancy | Date

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Daily News

No Need for Niacin? Meta-analysis Argues the End Is Nigh

Yael L. Maxwell

April 22, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Conference News CRT 2019

New ALERTS Data Support Use of Implantable Cardiac Monitor in High-Risk ACS Patients—With Caveats

Yael L. Maxwell

March 03, 2019

News Daily News

FDA Adds Boxed Warning About CV Risks to Gout Drug Febuxostat

Shelley Wood

February 22, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Vote

News Daily News

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Review

Caitlin E. Cox

January 11, 2019

News Daily News

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Michael O'Riordan

December 06, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

FDA Advisory Panel Gives Thumbs Up to EVAR System

Todd Neale

June 14, 2018

News Daily News

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

Michael O'Riordan

May 08, 2018

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

News Daily News

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Michael O'Riordan

April 24, 2018

News Industry News

Baim Institute Names Dr. C. Michael Gibson As CEO

December 05, 2017

News Conference News TCT 2017

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

Todd Neale

November 02, 2017

News Daily News

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

Shelley Wood

June 05, 2017

News Daily News

FDA Calls It Quits on Black-Box Warnings for Smoking Cessation Drugs

Shelley Wood

December 20, 2016

News Daily News

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Shelley Wood

December 02, 2016

Advertisement

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

No Need for Niacin? Meta-analysis Argues the End Is Nigh

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

New ALERTS Data Support Use of Implantable Cardiac Monitor in High-Risk ACS Patients—With Caveats

FDA Adds Boxed Warning About CV Risks to Gout Drug Febuxostat

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

TCTMD’s Top 10 Most Popular Stories for January 2019

Febuxostat Emerges Relatively Unscathed After FDA Advisory Committee Review

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

FDA Advisory Panel Gives Thumbs Up to EVAR System

Implantable Cardiac Monitor for High-Risk ACS Patients Wins FDA Approval

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Baim Institute Names Dr. C. Michael Gibson As CEO

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

FDA Calls It Quits on Black-Box Warnings for Smoking Cessation Drugs

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content